(Reuters) -Ironwood Pharmaceuticals said on Thursday that its treatment for a condition associated with chronic intestinal failure met the main goal in a late-stage trial.
The trial evaluted apraglutide in patients with short bowel syndrome with intestinal failure (SBS-IF), a condition which might lead to serious, life-threatening complications.
Ironwood plans to submit a marketing application based on the trial results.
(Reporting by Christy Santhosh; Editing by Savio D’Souza and Shounak Dasgupta)
